

Supplementary Table 1. Factors Associated with 30-Day Mortality in Patients with Persistent MRSA Bacteremia Who Underwent Antimicrobial Switching during Treatment

Variable	Overall (n=43)	Survived (n=34)	Deceased (n=9)	HR (95% CI)	p value
Sex, male	20 (46.5)	18 (52.9)	2 (22.2)	0.28 (0.06-1.36)	0.114
Age (yr)	71 (61–81)	70 (58–82)	81 (61.5–81)	1.02 (0.97–1.08)	0.102*
Vancomycin MIC \geq 1 mg/L	33 (76.7)	26 (76.5)	7 (77.8)	1.11 (0.23–5.36)	0.895
Initial treatment					
Definitive antimicrobial agents					0.868
Vancomycin	32 (74.4)	25 (73.5)	7 (77.8)	1.14 (0.24–5.51)	
Teicoplanin	11 (25.6)	9 (26.5)	2 (22.2)	Ref	
Beta-lactams co-administration	25 (58.1)	19 (55.9)	6 (66.7)	1.46 (0.37–5.85)	0.591
Time to active antibiotics (days)*	2 (1–3)	2 (0.75–3.25)	2 (0.5–3)	0.91 (0.68–1.22)	0.542
Treatment duration of initial antibiotics (days)	10 (7–17)	11.5 (7–20.5)	7 (6.5–10.5)	0.93 (0.89–0.97)	0.001*
Secondary agents					
Change to other glycopeptides	24 (55.8)	19 (55.9)	5 (55.6)	0.93 (0.25–3.47)	0.915
Change to linezolid	19 (44.2)	15 (44.1)	4 (44.4)	Ref	
Initial laboratory findings					
White blood cell count (/ μ L)	12380 (10560–14810)	12250 (10830–15100)	12390 (7750–13990)	1.03 (0.97–1.08)	0.332
C-reactive protein (mg/dL)	22.30 (8.78–27.50)	22.50 (9.13–27.71)	14.69 (8.33–29.26)	1.00 (0.94–1.06)	0.901
Disease severity					
ICU admission within 24 hours*	16 (37.2)	11 (32.4)	5 (55.6)	2.22 (0.60–8.27)	0.235
Pitt bacteremia score (initial)	1 (0–3)	1 (0–2)	3 (0.5–4)	1.21 (0.92–1.59)	0.171
Pitt bacteremia score (day 4)*	0 (0–2)	0 (0–2)	1 (0–5)	1.16 (0.90–1.51)	0.261
Focus of infection					
Endocarditis	6 (14.0)	4 (11.8)	2 (22.2)	2.10 (0.44–10.15)	0.356
Osteoarticular focus	13 (30.2)	12 (35.3)	1 (11.1)	0.27 (0.03–2.17)	0.271
Pneumonia	1 (2.3)	0 (0.0)	1 (11.1)	7.85 (0.92–67.20)	0.060*
Surgical wound infection	1 (2.3)	1 (2.9)	0 (0.0)	N/A	
Skin and soft tissue infection	6 (14.0)	6 (17.6)	0 (0.0)	N/A	
Intravascular catheter	7 (16.3)	4 (11.8)	3 (33.3)	2.85 (0.71–11.42)	0.139
Unknown focus	6 (14.0)	4 (11.8)	2 (22.2)	1.81 (0.38–8.73)	0.458
Metastatic infection	15 (34.9)	12 (35.3)	3 (33.3)	0.93 (0.23–3.73)	0.920
Echocardiography	36 (83.7)	29 (85.3)	7 (77.8)	0.58 (0.12–2.78)	0.491
Onset of bacteremia					
Nosocomial	22 (51.2)	18 (52.9)	4 (44.4)	Reference	
Healthcare-associated	12 (27.9)	9 (26.5)	3 (33.3)	1.54 (0.34–6.89)	
Community-acquired	9 (20.9)	7 (20.6)	2 (22.2)	1.13 (0.21–6.17)	
Bacteremia duration (days)	11 (6–19)	14 (6.5–21.25)	8 (6–11.5)	0.93 (0.84–1.02)	0.123*
Prostheses					
Orthopedic device	8 (18.6)	7 (20.6)	1 (11.1)	0.49 (0.06–3.85)	0.490
Cardiovascular device	2 (4.6)	2 (5.9)	0 (0.0)	NA	
Long-term CVC	8 (18.6)	7 (20.6)	1 (11.1)	0.50 (0.06–4.00)	0.513
Removal of eradicable focus					
No removal	15 (34.9)	13 (38.2)	2 (22.2)	Reference	
Non-eradicable	15 (34.9)	11 (32.4)	4 (44.4)	2.00 (0.37–10.91)	
Removal of focus after day 3*	4 (9.3)	3 (8.8)	1 (11.1)	1.82 (0.17–20.10)	
Removal of focus before day 3*	9 (20.9)	7 (20.6)	2 (22.2)	1.64 (0.23–11.64)	
Charlson comorbidity index	1 (0–4)	1 (0–3.25)	2 (1–5)	1.06 (0.84–1.35)	0.610
Immunosuppression	7 (16.3)	5 (14.7)	2 (22.2)	1.52 (0.32–7.32)	0.602
ID consultation within 7 days*	32 (74.4)	25 (73.5)	7 (77.8)	1.33 (0.28–6.40)	0.723

MRSA, methicillin-resistant *Staphylococcus aureus*; MIC, minimal inhibitory concentration; CVC, central venous catheter; ICU, intensive care unit; ID, infectious diseases; IQR, interquartile range; HR, hazard ratio; CI, confidence interval.

Data are presented as numbers (%) or median (interquartile range) unless otherwise indicated.

*Time points were calculated from the onset of bacteremia.